<DOC>
	<DOCNO>NCT02104843</DOCNO>
	<brief_summary>The primary purpose ass effect Daclatasvir ( DCV ) /Asunaprevir ( ASV ) /BMS-791325 combination therapy exposure Rosuvastatin .</brief_summary>
	<brief_title>Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 Rosuvastatin</brief_title>
	<detailed_description>IND Number : 79,599/101,943 Primary Purpose : Other - Phase 1 Clinical Pharmacology drug interaction study healthy subject</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy subject clinically significant deviation normal medical history , physical exam finding , 12 lead ECG measurement clinical laboratory test Females must nonchildbearing potential Women childbearing potential Any significant acute chronic medical condition Inability tolerate oral medication Inability venipunctured and/or tolerate venous access Abnormal liver function test Current recent ( within 3 month dose ) gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>